MedTrace Logo

SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

NCT06173947 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 411

Last updated 2025-05-21

No results posted yet for this study

Summary

In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.

Conditions

  • End Stage Liver Disease
  • Jaundice
  • Liver Dysfunction
  • Portal Hypertension

Interventions

DEVICE

FibroScan® Expert 630

The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Jinjun Chen, PHD · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-09-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06173947 on ClinicalTrials.gov